Thryv Therapeutics Targets LQTS with THRV-1268 Trial Launch
San Francisco, California, USA – April 22, 2026 In a significant advancement for rare cardiac disease therapeutics, Thryv Therapeutics...
FDA Fast Track
Advertisement
Polaryx Therapeutics Secures FDA Fast Track for PLX-200 in Rare Diseases
Paramus, New Jersey, USA, April 21, 2026 In a major regulatory advancement for rare disease therapeutics, Polaryx Therapeutics, Inc....
Radiopharm Theranostics Advances RAD101 Brain Imaging Trial
SYDNEY, April 16, 2026 Radiopharmaceutical innovation continues to reshape oncology diagnostics as Radiopharm Theranostics announced completion of enrollment in...
Affinia Therapeutics Wins Canada Nod for AFTX-201 Trial
Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...
Vedanta Biosciences Advances VE303 Phase 3 Trial in CDI
CAMBRIDGE, Mass., April 2, 2026 Vedanta Biosciences announced that its pivotal Phase 3 RESTORATiVE303 clinical trial of VE303 will...
Advertisements
Pasithea Wins FDA Fast Track for PAS-004 Cancer Drug
MIAMI, USA — April 1, 2026 Pasithea Therapeutics Corp. has announced that the U.S. Food and Drug Administration (FDA)...
Zymeworks’ ZW191 Gets FDA Fast Track for Cancer
VANCOUVER, British Columbia, March 30, 2026 Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to...
Rezpegaldesleukin Shows Strong Phase 2b Results in AD
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
FDA Fast Tracks ILD Imaging Radiotracer Innovation
LONDON, UK, Feb. 12, 2026 — Serac Healthcare announced that the U.S. Food and Drug Administration has granted Fast...
Advertisement
